![]() |
|
|
Vol. 289, Issue 1, 72-78, April 1999
Departments of
Virology (M.K., K.S.) and
Research Institute for
Wakan-Yaku (Traditional Sino-Japanese Medicines) (P.B., M.O., S.K.,
T.N.), Toyama Medical and Pharmaceutical University, Sugitani, Toyama,
Japan;
Central Research and Development Laboratory, Showa Shell Sekiyu
K.K., Atsugi, Kanagawa, Japan (T.H.); and
Department of Obstetrics and
Gynecology, Tokyo University Branch Hospital, Tokyo, Japan (T.K.)
Rhus javanica, a medicinal herb, has been shown to
exhibit oral therapeutic anti-herpes simplex virus (HSV) activity in
mice. We purified two major anti-HSV compounds, moronic acid and
betulonic acid, from the herbal extract by extraction with ethyl
acetate at pH 10 followed by chromatographic separations and examined their anti-HSV activity in vitro and in vivo. Moronic acid was quantitatively a major anti-HSV compound in the ethyl acetate-soluble fraction. The effective concentrations for 50% plaque reduction of
moronic acid and betulonic acid for wild-type HSV type 1 (HSV-1) were 3.9 and 2.6 µg/ml, respectively. The therapeutic index of moronic acid (10.3-16.3) was larger than that of betulonic acid (6.2).
Susceptibility of acyclovir-phosphonoacetic acid-resistant HSV-1,
thymidine kinase-deficient HSV-1, and wild-type HSV type 2 to moronic
acid was similar to that of the wild-type HSV-1. When this compound was
administered orally to mice infected cutaneously with HSV-1 three times
daily, it significantly retarded the development of skin lesions and/or
prolonged the mean survival times of infected mice without toxicity
compared with the control. Moronic acid suppressed virus yields in the
brain more efficiently than those in the skin. This was consistent with
the prolongation of mean survival times. Thus, moronic acid was
purified as a major anti-HSV compound from the herbal extract of
Rhus javanica. Mode of the anti-HSV activity was
different from that of ACV. Moronic acid showed oral therapeutic
efficacy in HSV-infected mice and possessed novel anti-HSV activity
that was consistent with that of the extract.
This article has been cited by other articles:
![]() |
M. Kurokawa, T. Hozumi, M. Tsurita, S. Kadota, T. Namba, and K. Shiraki Biological Characterization of Eugeniin as an Anti-Herpes Simplex Virus Type 1 Compound in Vitro and in Vivo J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 372 - 379. [Abstract] [Full Text] |
||||